Cytokines in severe infections: From pathophysiology to clinical applications

European Cytokine Network

Volumn 8, Issue 3, 1997, Pages 317-318

  Glauser, Michel P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; INFECTION; MACROPHAGE; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; SEPTIC SHOCK; SURVIVAL;

ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; CYTOKINES; HUMANS; INFECTION; LIPOPOLYSACCHARIDES; RECEPTORS, CYTOKINE; SHOCK, SEPTIC;

EID: 0030831128     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (6)

1. Heumann D, Barras C, Severin A, et al. 1994. Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect. Immun. 62: 2715.
2. Leturcq D, Moriarty A M, Talbott G, et al. 1995. Therapeutic strategies to block LPS interactions with its receptor. In: Bacterial endotoxins: lipopolysaccharides from genes to therapy. Wiley-Liss Inc, 473.
3. Abraham E, Wunderink R, Silverman H, Perl T M, Nasraway S, Levy H, et al. 1995. Efficacy and safety of monoclonal antibody to human tumor necrosis factor in patients with sepsis syndrome. A randomized controlled, double-blind multicenter clinical trial. TNF-α MAb sepsis study group. JAMA 273: 934.
4. Fisher C J Jr, Agosti J M, Opal S M, Lowry S F, Blak R A, Sadoff J C, Abraham E, Schein R, Benjamin E. 1996. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334: 1697.
5. Abraham E, Glauser M P, Butler T, Garbino J, Gelmont D, Laterre P, et al. 1997. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro45-2081 Study Group. JAMA 277: 1531.
6. Sprung C L, Finch R G, Thijs L G, Glauser M P. 1996. International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee. Crit. Care Med. 24: 1441.